share_log

Transcode Therapeutics | 8-K: Current report

Transcode Therapeutics | 8-K: Current report

Transcode Therapeutics | 8-K:重大事件
美股SEC公告 ·  06/08 04:03

Moomoo AI 已提取核心訊息

TransCode Therapeutics, Inc. has announced on June 3, 2024, that it received a notification from the Nasdaq Office of General Counsel confirming the company's compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. As a result of regaining compliance, the scheduled Nasdaq Hearings Panel on June 25, 2024, has been cancelled. The company, however, will remain under the mandatory panel monitor until January 27, 2025, as per Nasdaq Listing Rule 5815(d)(4)(B). This development follows previous concerns regarding TransCode's adherence to Nasdaq's listing standards.
TransCode Therapeutics, Inc. has announced on June 3, 2024, that it received a notification from the Nasdaq Office of General Counsel confirming the company's compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. As a result of regaining compliance, the scheduled Nasdaq Hearings Panel on June 25, 2024, has been cancelled. The company, however, will remain under the mandatory panel monitor until January 27, 2025, as per Nasdaq Listing Rule 5815(d)(4)(B). This development follows previous concerns regarding TransCode's adherence to Nasdaq's listing standards.
TransCode Therapeutics,Inc.宣佈於2024年6月3日收到納斯達克總顧問辦公室的通知,確認該公司遵守了納斯達克資本市場維持上市的最低買盤要求。由於重新符合規定,原定於2024年6月25日的納斯達克聽證會已被取消。然而,根據納斯達克上市規則5815(d)(4)(B)的規定,該公司將繼續受到強制委員會監督,直至2025年1月27日。這一進展是繼之前就TransCode遵守納斯達克上市標準提出關切之後的。
TransCode Therapeutics,Inc.宣佈於2024年6月3日收到納斯達克總顧問辦公室的通知,確認該公司遵守了納斯達克資本市場維持上市的最低買盤要求。由於重新符合規定,原定於2024年6月25日的納斯達克聽證會已被取消。然而,根據納斯達克上市規則5815(d)(4)(B)的規定,該公司將繼續受到強制委員會監督,直至2025年1月27日。這一進展是繼之前就TransCode遵守納斯達克上市標準提出關切之後的。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息